
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics demonstrated robust growth, with the physician channel expanding by approximately 20% and showing high-single-digit organic growth due to increased demand for tests and strong performance among large enterprise accounts. The company's total volumes increased by 16.3% year-over-year, surpassing expectations and indicating a healthy trajectory, bolstered by a 2.1% organic volume growth alongside advancements in diagnostics. Additionally, the sequential uptick in volume and expanded coverage suggest a positive outlook driven by the firm's strong position in the diagnostics market.
Bears say
Quest Diagnostics's financial outlook appears negative due to a decline in revenue per requisition, which fell by 0.4%, falling short of anticipated growth. Additionally, the potential impact of PAMA poses a significant headwind, estimated at around $100 million, with management expressing skepticism about achieving a permanent legislative solution. Despite some organic revenue growth attributed to testing strength, the overall financial metrics indicate underlying challenges that could impede profitability moving forward.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares